EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019

THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for...